News Quantified

BHVN – biohaven ltd. common shares (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Biohaven (BHVN) had its price target raised by TD Cowen from $15.00 to $30.00. They now have a "buy" rating on the stock.

Biohaven (BHVN) had its "strong-buy" rating reaffirmed by Raymond James Financial, Inc..

Biohaven (BHVN) had its price target lowered by HC Wainwright from $11.00 to $10.00. They now have a "neutral" rating on the stock.

Biohaven (BHVN) had its "outperform" rating reaffirmed by Leerink Partners.

Biohaven (BHVN) had its price target raised by Royal Bank Of Canada from $22.00 to $23.00. They now have an "outperform" rating on the stock.

-9.7%

BEAT

-7.7%

BEAT

-8.2%

BEAT

-5.1%

BEAT

Raymond James Financial, Inc.

Leerink Partners

Form DEFA14A Biohaven Ltd.

Form DEF 14A Biohaven Ltd. For: Apr 28

Form 4/A Biohaven Ltd. For: Mar 04 Filed by: CHILDS JOHN W

Form 4 Biohaven Ltd. For: Feb 27 Filed by: Buten Matthew

Form 4 Biohaven Ltd. For: Feb 27 Filed by: Gentile Kimberly

Top News Gainers

4/16 Form DEFA14A Biohaven Pharmaceutical 14.2%

2/10 Biohaven's Rimegepant Named To Cortellis 2020 Potential Blockbuster "Drugs to Watch" List 12.9%

7/22 Biohaven Provides Update On Phase 2/3 Alzheimer's Disease Clinical Trial: Over 400 Patients Enrolled 10.4%

9/4 Form 8-K Biohaven Pharmaceutical For: Sep 04 9.3%

2/27 Biohaven's NURTEC™ ODT (rimegepant) Receives FDA Approval for the Acute Treatment of Migraine in Adults 8.1%

7/15 Biohaven's Positive Phase 3 Trial of Rimegepant Zydis® Orally Dissolving Tablet for Acute Treatment of Migraine Published in The Lancet 7.6%

3/12 Form 5 Biohaven Pharmaceutical For: Dec 31 Filed by: Coric Vlad 7.2%

5/7 Form 8-K Biohaven Pharmaceutical For: May 07 6.5%

4/27 Biohaven Enters Into Agreement With Genpharm for Distribution of NURTEC™ ODT in the Middle East 5.9%

1/27 Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 5.7%

Top News Decliners

3/31 Form 8-K Biohaven Pharmaceutical For: Mar 30 -13.6%

6/17 Biohaven Announces Proposed Public Offering Of Common Shares -12.4%

1/10 Form 4 Biohaven Pharmaceutical For: Jan 08 Filed by: Stock Elyse -11.2%

12/17 Biohaven Pharma says acute migraine treatment succeeds in study [Reuters] -10.7%

1/28 Biohaven Announces Proposed Public Offering Of Common Shares -8.8%

6/18 Biohaven Announces Pricing Of $300 Million Public Offering Of Common Shares -7.2%

12/6 Biohaven Pharma to continue late-stage study of Alzheimer's treatment [Reuters] -7.0%

4/7 Biohaven Enters Into Collaboration With Cove, Leading Migraine Telemedicine Platform, To Enhance Accessibility Of NURTEC™ ODT -5.9%

2/10 Biohaven's Troriluzole Study For Generalized Anxiety Disorder (GAD) Misses Primary Endpoint -5.9%

3/30 Biohaven Achieves Positive Results in Pivotal Trial of Oral NURTEC™, Dosed Every Other Day, for the Preventive Treatment of Migraine -5.0%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day